Intensity Therapeutics Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

WESTPORT, Conn. , Sept. 5, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Lewis H.

Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds Data Presented at ASCO Showed that Lead Asset INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas Compared To Synthetic Controls INVINCIBLE Study Data Presented at ASCO Showed INT230-6 Following One Intratumoral Dose Can Cause Immune Priming in Historically Quiescent Breast Cancers WESTPORT, Conn. , Aug. 14, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update

Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn. , Aug. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets.

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

WESTPORT, Conn. , July 10, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that the underwriters of its previously announced initial public offering have fully exercised their option to purchase an additional 585,000 shares of its common public stock at the IPO offering price of $5.00 per share, less underwriting discounts and commissions.

Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds

WESTPORT, Conn. , July 5, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the closing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

Alliance Entertainment Holding Corp

Fidelis Insurance Holdings Ltd

GEN Restaurant Group Inc

Kodiak Gas Services Inc

Surf Air Mobility Inc

Savers Value Village Inc

Corp Inmobiliaria Vesta SAB de CV

Seven issuers began trading in the final week of June, six of which are eligible for inclusion in our IPO stats and four of which raised $100+ million. The largest for-profit thrift store chain in North America, Savers Value Village upsized and priced above the range to raise $401 million at a $3.1 billion market cap. No IPOs are currently scheduled to list in the week ahead, as markets take a break to celebrate the Fourth of July, although some small issuers may join the calendar during the week.

U.S. IPO Weekly Recap: Sizable Deals Close Out The Q2 IPO Market, Led By Thrift Store Savers

WESTPORT, Conn. , June 29, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.

Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds

INT230-6 Induced T-Cell Receptor Signaling, Macrophage Markers, and IL-18 and B-Cell Receptor Signaling Data Was Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2023 WESTPORT, Conn. , June 6, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc.  ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic Treatment Leading to a Systemic Immune Response in Hot or Cold Tumors, Is A New Way To Treat Sarcoma Results to be Presented Today, June 3, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting WESTPORT, Conn. , June 3, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral (IT) cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, will be presented this afternoon at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas

Study accepted for a Spotlight Session Poster Presentation WESTPORT, Conn. , Dec. 8, 2022 /PRNewswire/ --  Intensity Therapeutics, Inc.  ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, first-in-class immune-based cancer therapies designed to kill tumors and increase immune system recognition of cancers, today presented new data from the INVINCIBLE study in a live Spotlight Session Poster Presentation at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held at the Henry B.

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)

Data from Ongoing Phase 1/2 Study of INT230-6 Alone or in Combination with Ipilimumab (INTENSITY# IT-01; BMS# CA184-592) Selected for Oral Podium Presentation Exploratory Kaplan Meier Analysis of the refractory Sarcoma Population Shows that dosing INT230-6 Equivalent to 40% or More of the Patient's Tumor Burden During the Course of Therapy Results in a Median Overall Survival of 715 Days Compared to a mOS of 205 days or a Historical Refractory Sarcoma Control WESTPORT, Conn. , Nov. 18, 2022 /PRNewswire/ -- I ntensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that data from its open-label phase 1/2 study of novel lead asset, INT230-6, as a monotherapy or in combination with ipilimumab in adult subjects with metastatic sarcomas, will be presented today in an oral podium presentation, at the Connective Tissue Oncology Society Annual Meeting (CTOS) being held at the Vancouver Convention Center in Vancouver, BC, Canada from November 16 -19, 2022.

Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTO

Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors Combined with Pembrolizumab in a Population Consisting of Heavily Pretreated Patients with Primarily Pancreatic, Bile Duct, Colorectal, and Triple Negative Breast Cancer (n=24), Whose Cancer Progressed, the mOS was 205 Days Full Set of Results to be Presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting WESTPORT, Conn. , Nov. 11, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc.   ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral therapies designed to kill tumors and increase immune system recognition of cancers, announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with pembrolizumab in patients with relapsed, refractory and metastatic solid tumors, will be presented today at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting being held in Boston and virtually November 8-12, 2022.

Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers

Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single Injection of up to 100% of a Tumor was Observed During the Trial Within the Tumor Microenvironment, There was a Relative Increase in Abundance of CD8 Memory T, CD4 Naïve and B Cells Post-Treatment No Surgery was Delayed or Cancelled, and No Surgical Procedure Altered Results to be Presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting WESTPORT, Conn.

Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers

Intensity Therapeutics has filed to raise $10 million in an IPO. The firm is developing intratumoral injection treatment approaches for various cancer conditions.

Intensity Therapeutics Finalizes Terms For $10 Million IPO

News for Intensity Therapeutics Inc Stock (INTS)